We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd., announced on May 26th that it had acquired a 50% stake in RosVivo Therapeutics Inc., an American new drug developer, for about 5.5 million U.S. dollars.
Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd., said it has secured a 50% stake in RosVivo Therapeutics Inc., a U.S. new drug developer, as its first investment destination. RosVivo recently developed RSVI-301, a new drug pipeline that ...